While we have used a Pik3ca mutation/Apc loss driven mouse model to derive our transplantable syngeneic graft lines, our work confirms the ability to transplant murine tumours into immunocompetent mouse hosts and establishes the potential to use a range of different genetically-engineered, or carcinogen-induced, mouse models to generate panels of mouse syngeneic grafts, akin to human PDX panels. The gene discussed is APC; the disease is neoplasm.